Health Care • Biotechnology: Laboratory Analytical Instruments
$1,674.81 ▼ -43.80
(-2.55%)
MKT CAP: $33.56B • VOL: 189.7K
52W L $1,023 52W H $1,729
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$1,407
MEDIAN
$1,876
MEAN
$1,909
HIGH
$2,278
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE MTD TAPE
MTD // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $2,026.52 | $1,926.03 | 2025-02-14 | $1,524.08 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $2,110.26 | $1,976.28 | 2025-02-06 | $1,574.32 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $1,909.28 | $1,842.29 | 2025-01-29 | $1,607.82 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $1,708.31 | — | 2025-01-17 | $1,641.31 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $1,473.83 | $1,591.07 | 2025-01-09 | $1,490.58 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $1,993.02 | $1,741.80 | 2024-12-18 | $1,457.08 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $1,624.57 | $1,691.56 | 2024-12-04 | $1,557.57 | -4.3% | 48% | C |